Although some ROS inhibitors have shown immunomodulatory effects [19], based on our findings, the use of Nox1-selective inhibitors should be explored as an adjunct therapy (e.g., along with antivirals) to decrease the mortality and morbidity associated with influenza. Here, NOX1 is linked to influenza.